Clopidogrel Versus Cilostazol in Ischemic Stroke - Trial NCT06242132
Access comprehensive clinical trial information for NCT06242132 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 900 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kafrelsheikh University
Timeline & Enrollment
Phase 3
Feb 01, 2024
Jan 30, 2025
Primary Outcome
rate of new ischemic stroke,Rate of drug-related hemorrhagic complications
Summary
Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of
 ticagrelor administered within 24 hours of the first-ever moderate to severe ischemic stroke
 compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06242132
Non-Device Trial